Evidence map›Paper›PMID 32726329›Full record

ArticlePloS one2020

Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus.

Iman I Salama, Samia M Sami, Ghada A Abdellatif, Amira Mohsen, Hanaa Rasmy, Solaf Ahmed Kamel, Mona Hamed Ibrahim, Mona Mostafa, Walaa A Fouad, Hala M Raslan

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Iman I SalamaCommunity Medicine Department, National Research Centre, Cairo, Egypt.ORCID 0000-0001-8901-4625
Samia M SamiChild Health Department, National Research Centre, Cairo, Egypt.
Ghada A AbdellatifCommunity Medicine Department, National Research Centre, Cairo, Egypt.
Amira MohsenCommunity Medicine Department, National Research Centre, Cairo, Egypt.
Hanaa RasmyClinical and Chemical Pathology Department, Centre of Excellence, National Research Centre, Cairo, Egypt.
Solaf Ahmed KamelClinical and Chemical Pathology Department, Centre of Excellence, National Research Centre, Cairo, Egypt.
Mona Hamed IbrahimClinical and Chemical Pathology Department, Centre of Excellence, National Research Centre, Cairo, Egypt.
Mona MostafaInternal Medicine Department, National Research Centre, Cairo, Egypt.
Walaa A FouadCommunity Medicine Department, National Research Centre, Cairo, Egypt.
Hala M RaslanInternal Medicine Department, National Research Centre, Cairo, Egypt.
National Research Centre · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the potential value of some miRNAs as diagnostic biomarkers for mild cognitive impairment (MCI) among patients with type2 diabetes mellitus (T2DM) and to identify other risk factors for MCI among them.

methodsThis study enrolled 163 adults with T2DM using face to face interview. Cognitive function with its domains was assessed using Adenbrooke's Cognitive Examination III (ACE III). Lipid profile, glycated hemoglobin, and miR-128, miR-132, miR- 874, miR-134, miR-323, and miR-382 expressions, using quantitative real-time PCR, were assessed.

resultsMCI was detected among 59/163 (36.2%) patients with T2DM. Plasma expression of miR-132 was significantly higher in T2DM patients with MCI compared to those without MCI and to normal cognitive healthy individuals (median = 2, 1.1 and 1.2 respectively, P < 0.05. Logistic regression analysis showed that higher miR-132 expression with adjusted odds ratio (AOR): 1.2 (95% CI 1.0-1.3), female gender (AOR:2.1; 95%CI 1.0-4.3), education below postgraduate (secondary and university education with AOR: 9.5 & 19.4 respectively) were the significant predicting factors for MCI among T2DM patients. Using ROC curve, miR-132 was the only assayed miRNA that significantly differentiates T2DM patients with MCI from those with normal cognition with 72.3% sensitivity, 56.2% specificity, and 63.8% accuracy (P < 0.05). Other studied miRNAs showed lower sensitivity and specificity for detecting MCI among studied T2DM participants.

conclusionMCI affects nearly one-third of adult patients with T2DM. A significantly over expression of miR-132 was detected among T2DM with MCI compared to those with normal cognition.

Indexed as

AdultBiomarkersCognitionCognitive DysfunctionDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansLipidsMaleMicroRNAsMiddle AgedNeuropsychological TestsRisk FactorsBiomarkersGlycated HemoglobinLipidsMicroRNAs

Identifiers

PMID32726329
PMCPMC7390351
OpenAlexW4253238251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.